Daniel Graham

US Patent:

20200000957, Jan 2, 2020

Filed:

Feb 28, 2019

Appl. No.:

16/289535

Inventors:

- Edmonds WA, US
DAWSON BEALL - GAITHERSBURG MD, US
DANIEL GRAHAM - GREENWOOD VILLAGE CO, US
ROB MARTEL - GREENWOOD VILLAGE CO, US
ANGELA MITCHEL - GREENWOOD VILLAGE CO, US
CHRISTINE HAEFLING - GREENWOOD VILLAGE CO, US
PETER BROWN - GREENWOOD VILLAGE CO, US
RICH DEGERONIMO - GREENWOOD VILLAGE CO, US
JERRY KANELLOS - ELTHAM, AU
BELINDA WILMER - MARTINSBURG WV, US
SHIRLEY MIEKKA - COLORADO SPRINGS CO, US

International Classification:

A61L 15/64
A61F 13/02
A61L 26/00
A61L 15/44
A61K 38/36
A61K 38/48
A61L 15/58
A61L 15/38
A61L 15/26
A61F 13/00
A61L 15/18
A61L 15/28
A61L 15/32
A61L 15/22
C08L 89/00

Abstract:

Fibrin Sealant products are used for topical hemostasis and tissue adherence. They are composed of two main reagents, fibrinogen and thrombin. When mixed in solution fibrinogen is converted to fibrin upon the addition of activated thrombin. Therefore typically these two components are stored separately in a lyophilized or liquid state, and mixed, upon or immediately before, application to a patient. While effective, these products require significant preparation that must take place immediately before application, thus delaying treatment and limiting the use of these haemostatic products to the treatment of mild forms of low pressure and low volume bleeding. Attempts to eliminate this delay and expand the usefulness and effectiveness of these products have resulted in products produced by processes that require the separation of these components and their deposition in distinct layers within the product. The processes described herein permit the mixing of fibrinogen and thrombin during product manufacture, without excessive fibrin formation. The resulting ‘pre-mixed’ fibrin sealant material can then be stored in either a frozen or dried state, or suspended in a non-aqueous environment. Activation of the material to form therapeutic fibrin sealant is accomplished by permitting the product to thaw (if frozen) or by the addition of water or other aqueous fluid, including blood, or other bodily fluids, if dried or suspended in a non-aqueous environment. The resulting material can be used to make a product in which a pre-mixed form of activatable fibrin sealant is a desired component.

US Patent:

20180117210, May 3, 2018

Filed:

May 25, 2017

Appl. No.:

15/605660

Inventors:

- BELLEVUE WA, US
DAWSON BEALL - GAITHERSBURG MD, US
DANIEL GRAHAM - GREENWOOD VILLAGE CO, US
ROB MARTEL - GREENWOOD VILLAGE CO, US
ANGELA MITCHEL - GREENWOOD VILLAGE CO, US
CHRISTINE HAEFLING - GREENWOOD VILLAGE CO, US
PETER BROWN - GREENWOOD VILLAGE CO, US
RICH DEGERONIMO - GREENWOOD VILLAGE CO, US
JERRY KANELLOS - ELTHAM, AU
BELINDA WILMER - MARTINSBURG WV, US
SHIRLEY MIEKKA - COLORADO SPRINGS CO, US

International Classification:

A61L 15/64
A61F 13/02
A61L 15/44
A61K 38/36
A61K 38/48
A61L 15/58
A61L 15/38
A61L 15/26
A61F 13/00
A61L 15/18
A61L 15/28
A61L 15/32
A61L 26/00
A61L 15/22
C08L 89/00

Abstract:

Disclosed are solid dressings for treating wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings.